Search
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalIt is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Synonyms: (1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diolProducts: ANIMOX® 100 MG/ML SOLUCIÓN ORAL, NEVIOT® 100 MG CÁPSULA BLANDALeflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many othe...
Products: ARAVA 10 MG FTA, LEFLUNOMID ARISTO 10 MGFlumazenil
go.drugbank.com/drugs/DB01205ApprovedInvestigationalFumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine
Products: FLUMAZENIL-BAXTER SOLUTION FOR INJECTION 1 MG/10 ML, ANTİZEPİN 1 MG/10 ML İ.V. ENJEKSİYONLUK ÇÖZELTİ, 5 ADETRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141]
Products: LUCENTIS® 10 MG /ML SOLUCION INYECTABLE, LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGEVinorelbine
go.drugbank.com/drugs/DB00361ApprovedInvestigationalIt was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. … It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug [L2002].
Products: VINELBINE INJECTION 10 MG/ML, NAVELBINE INJECTION 10 mg/mlRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalAddition of weight-based ribavirin to Technivie therapy increased sustained virologic response after 12 weeks of daily therapy (SVR12) from 90% to 97% in patients with HCV genotype 1a and 90.9% to 100% … Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Products: VIRON 200 MG SERT KAPSUL, 140 ADET, VIRON 600 MG FİLM KAPLI TABLET, 14 ADETBisoprolol
go.drugbank.com/drugs/DB00612ApprovedInvestigational[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. … It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.
Mixtures: Concor AMLO 10 mg/10 mg - Tabletten, COSYREL FILM-COATED TABLET 10 mg/ 10 mgProducts: BISOPROLOL - CT 10 MG TABL, BISOPROLOLO EGApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApproximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].
Products: ERLEADA ®TABLETAS RECUBIERTAS 60 MGNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001] … [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Categories: Immunoglobulin GProducts: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, OPDIVO 100 INF. IÇIN KONS. IÇEREN FLAKON, 1 ADETHydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[L8072] It was developed during World War II as a derivative of [quinacrine] with less severe side effects. … [L8072] It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus.
Products: PLAQUENIL 200 MG FILM KAPLI TABLET, 60 ADET, HALOXIN TABLET 100 mg